LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article: Erratum: Targeting gut microbiota: a potential promising therapy for diabetic kidney disease.

    Chen, Zhonge / Zhu, Shuishan / Xu, Gaosi

    American journal of translational research

    2018  Volume 10, Issue 1, Page(s) 333

    Abstract: This corrects the article on p. 4009 in vol. 8, PMID: 27829988.]. ...

    Abstract [This corrects the article on p. 4009 in vol. 8, PMID: 27829988.].
    Language English
    Publishing date 2018-01-15
    Publishing country United States
    Document type Journal Article ; Published Erratum
    ZDB-ID 2471058-1
    ISSN 1943-8141
    ISSN 1943-8141
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Targeting gut microbiota: a potential promising therapy for diabetic kidney disease.

    Chen, Zhonge / Zhu, Shuishan / Xu, Gaosi

    American journal of translational research

    2016  Volume 8, Issue 10, Page(s) 4009–4016

    Abstract: ... to pharmacologically control the metabolites of microbiota, the gut microbiota represents a new potential therapeutic ... of diabetes mellitus (DM) and end-stage renal disease (ESRD). However, the mechanism through which gut microbiota ... influence diabetic kidney disease (DKD) is ignored. In the present article, we reviewed the changes in gut ...

    Abstract Conventional studies reveal a contributory role of gut microbiota in the process of diabetes mellitus (DM) and end-stage renal disease (ESRD). However, the mechanism through which gut microbiota influence diabetic kidney disease (DKD) is ignored. In the present article, we reviewed the changes in gut microbiota of patients with DM, DKD as well as ESRD, and how this may contribute to the progression of DKD. Although further studies are needed to either selectively change the composition of the gut microbiota or to pharmacologically control the metabolites of microbiota, the gut microbiota represents a new potential therapeutic target for DKD.
    Language English
    Publishing date 2016-10-15
    Publishing country United States
    Document type Review ; Journal Article
    ZDB-ID 2471058-1
    ISSN 1943-8141
    ISSN 1943-8141
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Traditional Chinese medicine improved diabetic kidney disease through targeting gut microbiota.

    Wu, Xia-Qing / Zhao, Lei / Zhao, Yan-Long / He, Xin-Yao / Zou, Liang / Zhao, Ying-Yong / Li, Xia

    Pharmaceutical biology

    2024  Volume 62, Issue 1, Page(s) 423–435

    Abstract: ... The following keywords were used: diabetic kidney disease, diabetic nephropathy, gut microbiota, natural product ... Traditional Chinese medicine (TCM) has shown promising outcomes in ameliorating DKD by addressing the gut microbiota ... potential candidates to address the gut-kidney axis. TCM interventions offer a significant therapeutic ...

    Abstract Context: Diabetic kidney disease (DKD) affects nearly 40% of diabetic patients, often leading to end-stage renal disease that requires renal replacement therapies, such as dialysis and transplantation. The gut microbiota, an integral aspect of human evolution, plays a crucial role in this condition. Traditional Chinese medicine (TCM) has shown promising outcomes in ameliorating DKD by addressing the gut microbiota.
    Objective: This review elucidates the modifications in gut microbiota observed in DKD and explores the impact of TCM interventions on correcting microbial dysregulation.
    Methods: We searched relevant articles from databases including Web of Science, PubMed, ScienceDirect, Wiley, and Springer Nature. The following keywords were used: diabetic kidney disease, diabetic nephropathy, gut microbiota, natural product, TCM, Chinese herbal medicine, and Chinese medicinal herbs. Rigorous criteria were applied to identify high-quality studies on TCM interventions against DKD.
    Results: Dysregulation of the gut microbiota, including
    Conclusion: This review highlights the importance of targeting the gut-kidney axis to regulate microbial disorders, their metabolites, and associated signaling pathways in DKD. The Qing-Re-Xiao-Zheng formula, the Shenyan Kangfu tablet, the Huangkui capsule, and the Bekhogainsam decoction are potential candidates to address the gut-kidney axis. TCM interventions offer a significant therapeutic approach by targeting microbial dysregulation in patients with DKD.
    MeSH term(s) Gastrointestinal Microbiome/drug effects ; Gastrointestinal Microbiome/physiology ; Humans ; Diabetic Nephropathies/drug therapy ; Medicine, Chinese Traditional/methods ; Drugs, Chinese Herbal/pharmacology ; Drugs, Chinese Herbal/therapeutic use ; Animals
    Language English
    Publishing date 2024-05-17
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1440131-9
    ISSN 1744-5116 ; 1388-0209
    ISSN (online) 1744-5116
    ISSN 1388-0209
    DOI 10.1080/13880209.2024.2351946
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 1300: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: New therapeutic targets in chronic kidney disease progression and renal fibrosis.

    Rayego-Mateos, Sandra / Valdivielso, Jose M

    Expert opinion on therapeutic targets

    2020  Volume 24, Issue 7, Page(s) 655–670

    Abstract: ... a promising field because of the interaction between the gut microbiota and the renal system. ... of the specific inducers of inflammation in the kidney is an area of heightened potential. Prevention ... Introduction: The current therapeutic armamentarium to prevent chronic kidney disease (CKD ...

    Abstract Introduction: The current therapeutic armamentarium to prevent chronic kidney disease (CKD) progression is limited to the control of blood pressure and in diabetic patients, the strict control of glucose levels. Current research is primarily focused on the reduction of inflammation and fibrosis at different levels.
    Areas covered: This article examines the latest progress in this field and places an emphasis on inflammation, oxidative stress, and fibrosis. New therapeutic targets are described and evidence from experimental and clinical studies is summarized. We performed a search in Medline for articles published over the last 10 years.
    Expert opinion: The search for therapeutic targets of renal inflammation is hindered by an incomplete understanding of the pathophysiology. The determination of the specific inducers of inflammation in the kidney is an area of heightened potential. Prevention of the progression of renal fibrosis by blocking TGF-β signaling has been unsuccessful, but the investigation of signaling pathways involved in late stages of fibrosis progression could yield improved results. Preventive strategies such as the modification of microbiota-inducers of uremic toxins involved in CKD progression is a promising field because of the interaction between the gut microbiota and the renal system.
    MeSH term(s) Animals ; Disease Progression ; Fibrosis/pathology ; Fibrosis/therapy ; Gastrointestinal Microbiome ; Humans ; Inflammation/physiopathology ; Inflammation/therapy ; Molecular Targeted Therapy ; Oxidative Stress ; Renal Insufficiency, Chronic/physiopathology ; Renal Insufficiency, Chronic/therapy
    Language English
    Publishing date 2020-05-18
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2055208-7
    ISSN 1744-7631 ; 1472-8222
    ISSN (online) 1744-7631
    ISSN 1472-8222
    DOI 10.1080/14728222.2020.1762173
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5244: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top